Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.